Exchange: NASDAQ Sector: Healthcare Industry: Health Information Services
Current Signal: SELL (auto-tracking)
-0.91% $16.30
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 605.64 mill |
EPS: | -0.350 |
P/E: | -46.57 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 159.86 mill |
Avg Daily Volume: | 0.549 mill |
RATING 2024-04-25 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -46.57 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -46.57 | industry: PE -4.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$7.67 (-52.94%) $-8.63 |
Date: 2024-04-25 |
Expected Trading Range (DAY) |
---|
$ 15.56 - 17.04 ( +/- 4.52%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Feehery William F | Buy | 124 779 | Restricted Stock Units |
2024-04-02 | Smith Patrick F | Sell | 5 264 | Common Stock |
2024-04-02 | Smith Patrick F | Sell | 649 | Common Stock |
2024-04-02 | Smith Patrick F | Sell | 3 024 | Common Stock |
2024-04-02 | Smith Patrick F | Sell | 328 | Common Stock |
INSIDER POWER |
---|
30.49 |
Last 100 transactions |
Buy: 798 344 | Sell: 442 671 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $16.30 (-0.91% ) |
Volume | 0.344 mill |
Avg. Vol. | 0.549 mill |
% of Avg. Vol | 62.56 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $16.81 | N/A | Active |
---|
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.